In a surprising move, Novo Nordisk joined forces in April with Dudum’s telehealth company, Hims & Hers, in a bid to expand sales of Wegovy to the growing pool of online patients.

De novo grows up Beyond explaining how de novo genes are regulated, the findings may shed light on how de novo genes are formed in the first place.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% year-to-date due to multiple headwinds.

Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Novo Nordisk A/S ...

Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy – Hagens Berman ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.